Vendor, West Lafayette, IN
Eradivir Inc.
UEI QGDJNUMU9VR6, CAGE 8KVH1
1 award and $0 obligated between February 14, 2024 and September 10, 2024, 100% under full and open competition, against 1.0 offers on average where reported.
Industries
NAICS on the awards, by dollars.
| Research and Development in Biotechnology (except Nanobiotechnology)NAICS 541714 | $0 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 1 |
| Definitive Contract | 1 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75A50123C00039Definitive Contract, February 14, 2024, Full and Open Competition, 1 offers | Barda - Aspr / Daappo / Barda DCMAOffice of Assistant Secretary for Preparedness and Response | Eradivir INC. Ind Studies Is to Complete a Package of Glp-Compliant Nonclinical Safety Studies That Will Support a Successful Initial Ind ApNAICS 541714, PSC AN13 | $0 |
- Places of performance
- Pennsylvania
- Product and service codes
- AN13 Health R&D Services; Health Care Services; Experimental Development
- Transactions
- 3 across 1 awards